Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Assets (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Non-Current Assets for 11 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • Quarterly Non-Current Assets fell 15.33% to $4.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Sep 2025, down 14.9% year-over-year, with the annual reading at $4.9 million for FY2024, 14.61% down from the prior year.
  • Non-Current Assets hit $4.3 million in Q3 2025 for Aptevo Therapeutics, down from $4.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $7.4 million in Q2 2022 to a low of $3.5 million in Q1 2022.
  • Historically, Non-Current Assets has averaged $5.5 million across 5 years, with a median of $5.6 million in 2024.
  • Biggest five-year swings in Non-Current Assets: crashed 43.34% in 2021 and later surged 84.62% in 2023.
  • Year by year, Non-Current Assets stood at $4.0 million in 2021, then soared by 67.82% to $6.8 million in 2022, then fell by 14.62% to $5.8 million in 2023, then dropped by 14.61% to $4.9 million in 2024, then decreased by 11.86% to $4.3 million in 2025.
  • Business Quant data shows Non-Current Assets for APVO at $4.3 million in Q3 2025, $4.5 million in Q2 2025, and $4.7 million in Q1 2025.